Concarlo Therapeutics

?? We are excited to share this article written by our founder & CEO, Stacy Blain in Drug Discovery & Development! It highlights the importance of ???????????????? ?????? ???? ?????????????? ????????/??/?? ?????????????????and how this novel approach could shape the future of the industry. Check out her article and see how Concarlo Therapeutics' inhibitors and its focus on p27 bring true innovation to the field. #Oncology #CancerResearch #p27Inhibitor #TargetedTherapies #ConcarloTherapeutics #SmallMolecule #CDK4 #CDK2 https://lnkd.in/e5PnYwqN

Exciting times in oncology with Roche’s inavolisib, a PI3K inhibitor, advancing breast cancer therapy. ??? The FDA has approved inavolisib (Itovebi, Genentech, Inc.) in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative advanced breast cancer. This is a significant step forward for patients with locally advanced or metastatic breast cancer, offering a new option where previous therapies have failed. ? While PI3K targeting shows potential, it's vital to explore alternative, more selective pathways for patients with drug-resistant cancers. At Concarlo Therapeutics, we're pushing forward with our p27 inhibitor, targeting the master regulator of cell cycle that drives tumor growth. We believe our approach could lead to fewer side effects and broader applications across a multitude of cancer types modulated by p27. ??? ? Looking forward to continued progress as we work to revolutionize cancer therapy. ???? ? #Oncology #BreastCancer #CancerResearch #BiotechInnovation #p27Inhibitor #TargetedTherapies #ConcarloTherapeutics #CancerCare https://lnkd.in/gxCufaRj

New Treatment Options The recent development in subclassifying HER2-negative breast cancer into HER2-low and HER2-ultralow represents a significant shift in the treatment landscape. With therapies like Enhertu now demonstrating responses in these newly defined patient groups, approximately 90% of patients with #MetastaticeBreastCancer could potentially benefit. While still a form of chemotherapy, sequencing Enhertu’s use will play a key role in optimizing patient outcomes, offering another vital option for those affected. This evolution in treatment closely aligns with Concarlo Therapeutics' mission to advance personalized cancer care. We focus on innovation in safer, more effective and durable therapies for patients with metastatic breast cancer with p27 targeted approaches. ? ? #ImproveOutcomes #BreastCancer #BreastCancerAwarenessMonth #BCAM #EmpowermentThroughInnovation https://lnkd.in/eCPt5g4k?

Reflecting on last year’s insights from our CEO, Stacy Blain: "Metastatic breast cancer remains an indomitable foe, but the incessant progress in research and treatment offers hope to those ensnared by the grip of this devastating disease. Awareness, advocacy, and financial support are not optional but rather essential in the pursuit of improving the lives of MBC patients and, ultimately, in the quest to unearth a cure."? Read the full article on Fempower Health. ? https://lnkd.in/eb3F58C8 #MBCAwarenessDay #MetastaticBreastCancerAwarenessDay #BreastCancerAwarenessMonth?

New Treatment Options #Ribociclib, Novartis’ CDK4/6 inhibitor, has now been FDA approved as adjuvant treatment for people diagnosed with HR+/HER2- stage II and III early breast cancer. Previously, Ribocicib had only been approved for advanced stage breast cancer patients. This approval represents a new choice for patients to manage the potential progression of their disease. #PatientEmpowerment #EarlyBreastCancer #BreastCancerAwarenessMonth?#BCAM https://lnkd.in/gBRWwM_Z?

Inhibiting CDKs has long been a goal in the field of oncology. While CDK4/6 inhibitors, like palbociclib, abemaciclib, and ribociclib have transformed the metastatic breast cancer space, the development of resistance is an ongoing issue with this class of drugs. New CDK4 inhibitors and CDK2 inhibitors have entered the conversation and are starting to report some early results. The announcement last week of Genentech’s acquisition of Regor Therapeutics Group’s CDK pipeline demonstrates that these are hot targets. Regor’s RGT-419B is a potent CDK4 inhibitor, with a low level of CDK2 inhibitor activity, and they suggest that it will combat resistance with a better toxicity profile. The idea behind CDK4 versus CDK6 inhibition is to reduce the neutropenia seen with CDK4/6 inhibitor by avoiding CDK6, which is the dominant CDK in hematopoietic lineages. Abemaciclib, which is a CDK6-sparing inhibitor demonstrates less neutropenia than that seen by either palbociclib or ribociclib, which are CDK4 inhibitors that are not as CDK6-sparing. But CDK6 overexpression is seen as a clinical resistance mechanism in the presence of CDK4/6 inhibitor. So, will this be the new dominant form of resistance seen clinically? And Pfizer’s Atirmociclib does appear to have significant Grade 3 neutropenia, so it is unclear whether the CDK6-sparing model is entirely correct. ????????????????'?? approach is different:?our small molecules inhibit CDK2/4/6 simultaneously in a coordinated manner by targeting the master regulator p27. Concarlo’s p27 inhibition is the only approach currently being investigated, as a means to inhibit all three critical CDKs with a single molecule, and this approach has several key differentiation features: ? Act as molecular glues to inhibit CDK2/4/6 simultaneously to provide potent response in drug-resistant tumors ? Fewer dose-limiting toxicities such as neutropenia, which could translate to longer duration of response (DOR) ? Induction of tumor cell death as opposed to just slowing tumor growth, resulting in tumor regression vs. tumor stasis ? Increased response when combined with other inhibitors, such as palbociclib, or RAS/MAPK pathway inhibitors ? The CDK inhibitor space is heating up. ?? Get in touch with us to learn about our innovative approach. https://lnkd.in/eQe_3yNT OncologyPipeline Jacob Plieth #RegorTherapeutics #Roche #Pfizer #Tumors #BreastCancer #SmallMolecule #CDK4 #CDK2 #Novartis #Lilly

Throwback to this insightful piece from our CEO, Stacy Blain. These perspectives continue to resonate and remain relevant today. “One of the biggest roadblocks for breast cancer patients is the problem of drug resistance. Overcoming this pervasive factor calls for a paradigm shift. One that’s willing to reopen the focus on targets that were previously deemed untargetable—and undruggable—in order to prevent drug resistant phenotypes. That’s where we’ve focused our efforts at Concarlo Therapeutics.”? #BreastCancerAwarenessMonth #BCAM #BreastCancer #DrugResistance

Throwback to this insightful piece from our CEO, Stacy Blain. These perspectives continue to resonate and remain relevant today. “One of the biggest roadblocks for breast cancer patients is the problem of drug resistance. Overcoming this pervasive factor calls for a paradigm shift. One that’s willing to reopen the focus on targets that were previously deemed untargetable—and undruggable—in order to prevent drug resistant phenotypes. That’s where we’ve focused our efforts at Concarlo Therapeutics.”? #BreastCancerAwarenessMonth #BCAM #BreastCancer #DrugResistance

Concarlo Therapeutics is dedicated to advancing research and raising awareness in the fight against breast cancer.? Breast Cancer deserves more than a month.?? #CancerAwareness #BreastCancerAwareness #BCAM?

Today is World Cancer Research Day! We support this movement of raising awareness about the importance of cancer research and celebrating the breakthroughs made possible by researchers. ? Concarlo Therapeutics is deeply committed in advancing our novel therapeutic strategies to treat drug-resistant cancers and achieve our vision to create a world of?possibility, hope and time by making cancer a treatable, manageable and survivable condition. ? #CancerResearch #WorldCancerResearchDay